Table 4.
Demographic and Clinical Characteristics of L-AmB-Treated Patients in Case Series
| Patient Demographics | No. (%) |
|---|---|
| Total No. of patients | 846 |
| No. of patients who received L-AmB | 390 |
| Weighted median age, y | 40.41 |
| Patients age <18 ya | 56 (16.77) |
| Male patienta | 282 (77.05) |
| Type of populationa | |
| Local (endemic area) | 205 (52.56) |
| Migrants | 19 (5.12) |
| Travelers | 147 (39.62) |
| Region of acquisition | |
| Americas | 271 (69.49) |
| Europe | 18 (4.62) |
| North Africa | 7 (1.79) |
| Sub-Saharan Africa | 0 (0) |
| Middle East/Asia | 60 (15.38) |
| Not available | 28 (7.18) |
| No. of immunocompromiseda | 30 (10.03) |
| Type of immunosuppression, No. (% of IC) | |
| HIV/AIDS | 11 (36.67) |
| RAID | 8 (26.67) |
| IBD | 4 (13.33) |
| AI | 3 (10) |
| OID | 2 (6.67) |
| SOT | 1 (3.33) |
| PULM | 1 (3.33) |
| Old World vs New World | |
| Old World | 113 (28.97) |
| New World | 271 (69.49) |
| Not available | 6 (1.54) |
| Clinical form | |
| CL | 248 (63.59) |
| ML | 107 (27.44) |
| MCL | 10 (2.56) |
| DL | 24 (6.15) |
| LR | 1 (0.26) |
| Leishmania complexes | |
| L. major | 13 (3.33) |
| L. tropica | 52 (13.33) |
| L. donovani | 29 (7.44) |
| L. mexicana | 3 (0.77) |
| L. braziliensis | 118 (30.26) |
| L. guyanensis | 38 (9.74) |
| Not available | 137 (35.13) |
Abbreviations: AI, autoimmune disease not otherwise specified; CL, cutaneous leishmaniasis; DL, disseminated/diffuse leishmaniasis; IBD, intestinal bowel disease; LR, leishmaniasis recidivans; MCL, mucocutaneous leishmaniasis; ML, mucosal leishmaniasis; OID, other immune disorders; PULM, pulmonary disease (asthma, chronic obstructive pulmonary disease); RAID, rheumatoid autoimmune disease; SOT, solid organ transplant.
a
The denominator used is the number of patients for which this variable was reported.